Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma
Academic Radiology · 2026-08 · 33 (8) · 3272-3278
DOI: 10.1016/j.acra.2026.02.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academic Radiology, 2026-08. Verfasst von Shams Iqbal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (S.I., K.H.…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Radiofrequency Ablation, Catheter Ablation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
RATIONALE AND OBJECTIVES Cholangiocarcinoma (CCA) is an aggressive malignancy often diagnosed at an advanced stage, precluding curative resection. In such patients, palliative interventions to relieve biliary obstruction are critical. Endobiliary radiofrequency ablation (RFA) using the Habib™ EndoHPB probe has been explored as an adjunct to improve biliary patency, though its percutaneous application and complication rate remain underexplored. MATERIALS AND METHODS We retrospectively reviewed eight patients (mean age: 59.9 ± 6.2 years; four males, four females) with unresectable intrahepatic/perihilar CCA who underwent percutaneous endobiliary RFA between January 2022 and June 2025. Outcomes included technical and clinical success, laboratory trends, adverse events, and interventional radiology (IR) service utilization. RESULTS Technical success was achieved in all patients (100%). Clinical success, defined as ≥50% bilirubin reduction from baseline within one month, and either symptom resolution within 14 days or improvement in biliary obstruction-related clinical parameters, was observed in seven patients (87.5%). No major procedure-related adverse events were noted, including vascular complications, despite endobiliary ablation. Following RFA, mean total bilirubin decreased from 5.5 ± 7.6 mg/dL to 2.7 ± 2.7 mg/dL at one month (p = 0.187). Aspartate aminotransferase (AST) declined from 85.9 ± 48.1 U/L to 59.7 ± 39.5 U/L (p = 0.005), and alanine aminotransferase (ALT) decreased from 104.7 ± 76.2 U/L to 56.1 ± 50.8 U/L (p = 0.054). The frequency of drain exchanges improved, with intervals extending from 1-3 weeks pre-RFA to 4-8 weeks post-RFA. Over a mean follow-up of 398.6 ± 562.3 days, three patients (37.5%) achieved drain internalization, while two deaths were attributed to disease progression. CONCLUSION Percutaneous endobiliary RFA with the Habib probe is safe, technically feasible, and associated with favorable laboratory and clinical outcomes in unresectable CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (S.I., K.H., R.A., R.U., S.Z., T.A., R.W.).
- Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (S.I., K.H., R.A., R.U., S.Z., T.A., R.W.). Electronic address: hegdekausthubh@gm…
- Medical Oncologist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (H.E.).
Zitieren
APA
Iqbal, S., Hegde, K., Arellano, R., Uppot, R., Zhao, S., An, T., Ellis, H., & Weissleder, R. (2026). Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma. Academic Radiology, 33(8), 3272-3278. https://doi.org/10.1016/j.acra.2026.02.034
Vancouver
Iqbal S, Hegde K, Arellano R, Uppot R, Zhao S, An T, et al. Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma. Academic Radiology. 2026;33(8):3272-3278. doi:10.1016/j.acra.2026.02.034
BibTeX
@article{Iqbal2026,
author = {Iqbal, Shams and Hegde, Kausthubh and Arellano, Ronald and Uppot, Raul and Zhao, Sara and An, Thomas and Ellis, Haley and Weissleder, Ralph},
title = {Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma},
journal = {Academic Radiology},
year = {2026},
volume = {33},
number = {8},
pages = {3272--3278},
doi = {10.1016/j.acra.2026.02.034}
}
EUVIMED